The most valuable predictors included the past/present medical history of CAD/CHF and/or stage 3–5 CKD, BUN, and CRP, and therefore the cost of such screening analysis does not exceed 15 USD or EUR that is important for the medical economy, in particular in the middle- and low-income countries. Here, CRP is linked to chronic kidney disease.